Detalhe da pesquisa
1.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(19): 1739-1754, 2023 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163621
2.
MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 - a Nordic Lymphoma Group study.
Haematologica
; 109(4): 1171-1183, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646663
3.
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established highrisk factors.
Haematologica
; 108(4): 1092-1104, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36519324
4.
Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience.
Hematol Oncol
; 40(1): 22-30, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34713465
5.
p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma.
Br J Haematol
; 191(5): 796-805, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32748433
6.
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.
Blood
; 131(21): 2357-2366, 2018 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29483101
7.
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
Blood
; 130(17): 1903-1910, 2017 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28819011
8.
Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment.
Haematologica
; 104(4): 789-796, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30514802
9.
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.
Br J Haematol
; 180(5): 666-679, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29318593
10.
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.
Blood
; 128(14): 1814-1820, 2016 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27354719
11.
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Biol Blood Marrow Transplant
; 23(3): 428-435, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28039078
12.
Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL.
Blood
; 135(22): 2000-2004, 2020 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32181815
13.
miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.
Blood
; 125(17): 2669-77, 2015 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-25736311
14.
Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.
Blood
; 125(5): 856-9, 2015 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-25634617
15.
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
Br J Haematol
; 175(3): 410-418, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27378674
16.
Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.
Blood
; 124(8): 1288-95, 2014 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-24859361
17.
Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.
Blood
; 123(21): 3255-62, 2014 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-24735962
18.
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.
Blood
; 123(19): 2953-9, 2014 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-24652994
19.
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.
Blood
; 124(3): 420-5, 2014 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24916506
20.
Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.
Lancet Oncol
; 16(13): 1370-9, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26377300